Home / Healthcare / Cellmid Limited - Product Pipeline Review - 2015

Cellmid Limited - Product Pipeline Review - 2015

Published: Oct 2015 | No Of Pages: 30 | Published By: Global Markets Direct

Summary

Global Markets Direct’s, ‘Cellmid Limited - Product Pipeline Review - 2015’, provides an overview of the Cellmid Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cellmid Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Cellmid Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cellmid Limited’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Cellmid Limited’s pipeline products

Reasons to buy

- Evaluate Cellmid Limited’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cellmid Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cellmid Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cellmid Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cellmid Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cellmid Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents 2
List of Tables 4
List of Figures 4
Cellmid Limited Snapshot 5
Cellmid Limited Overview 5
Key Information 5
Key Facts 5
Cellmid Limited - Research and Development Overview 6
Key Therapeutic Areas 6
Cellmid Limited - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Cellmid Limited - Pipeline Products Glance 10
Cellmid Limited - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Cellmid Limited - Drug Profiles 12
Antisense RNAi Oligonucleotides to Inhibit Midkine for Cardiovascular Diseases 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
CAB-101 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
CAB-102 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
CMK-103 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
hu-91 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibody to Inhibit Midkine for Cancer and Inflammatory Disorders 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Monoclonal Antibodies to Inhibit Midkine for Cancer 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Cellmid Limited - Pipeline Analysis 22
Cellmid Limited - Pipeline Products by Target 22
Cellmid Limited - Pipeline Products by Molecule Type 23
Cellmid Limited - Pipeline Products by Mechanism of Action 24
Cellmid Limited - Recent Pipeline Updates 25
Cellmid Limited - Dormant Projects 27
Cellmid Limited - Dormant Projects 27
Cellmid Limited - Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 29
Disclaimer 30

Cellmid Limited, Key Information 5
Cellmid Limited, Key Facts 5
Cellmid Limited - Pipeline by Indication, 2015 7
Cellmid Limited - Pipeline by Stage of Development, 2015 8
Cellmid Limited - Monotherapy Products in Pipeline, 2015 9
Cellmid Limited - Preclinical, 2015 10
Cellmid Limited - Discovery, 2015 11
Cellmid Limited - Pipeline by Target, 2015 22
Cellmid Limited - Pipeline by Molecule Type, 2015 23
Cellmid Limited - Pipeline Products by Mechanism of Action, 2015 24
Cellmid Limited - Recent Pipeline Updates, 2015 25
Cellmid Limited - Dormant Developmental Projects,2015 27
Cellmid Limited, Subsidiaries 28

Cellmid Limited - Pipeline by Top 10 Indication, 2015 7
Cellmid Limited - Pipeline by Stage of Development, 2015 8
Cellmid Limited - Monotherapy Products in Pipeline, 2015 9
Cellmid Limited - Pipeline by Top 10 Target, 2015 22
Cellmid Limited - Pipeline by Top 10 Molecule Type, 2015 23
Cellmid Limited - Pipeline Products by Top 10 Mechanism of Action, 2015 24

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +